Summary

Organization name

Profile

Kuros is a biomedical company that develops novel bioactive and biomaterial combination products for localised therapy.

Kuros products retain biologically active molecules at the site of action by incorporation into injectable matrices. These products combine the ease of injectablity with localised delivery, tunable release profiles and safety.  Kuros can use natural (fibrin-based) or synthetic matrices and has a number of methodologies for the retention and release of the biologically active molecules.

Kuros´ current product pipeline is based on its two types of matrices, fibrin a natural biomaterial that is the main structural component of blood clots and a synthetic matrix technology developed by Kuros. Kuros has developed this new matrix as synthetic biomaterials allow an increased degree of tailoring of the physical characteristics of the matrix (e.g. elasticity, strength, rate of biodegradation).

Kuros has entered into a major license & collaboration agreement with Baxter Healthcare Corporation. The collaboration covers the development of a number of biological combination products targeted at certain skin and orthopaedic indications. These products are all based on Kuros unique expertise to develop fibrin-bound growth factors for localized tissue repair.

They are actively diversifying and expanding their pipeline and are interested in in-licensing, partnering or collaboration opportunities in areas which complement their existing product portfolio or utilize their localized delivery technology.

Kuros is interested in:

• programs e.g. bioactives in musculoskeletal, wound and other therapeutic areas requiring localized delivery.
• discussing opportunities around complementary technology platforms.

Kuros has a flexible approach to deal structuring and aims to create relationships that maximize the value for both parties.    

Contact data are provided online.

URL

Your feedback

back